Label‐free characterization of an extracellular vesicle‐based therapeutic. Issue 12 (20th October 2021)

• Record Type: Journal Article
• Authors: Priglinger, Eleni; Strasser, Juergen; Buchroithner, Boris; Weber, Florian; Wolbank, Susanne; Auer, Daniela; Grasmann, Eva; Arzt, Claudia; Sivun, Dmitry; Grillari, Johannes; Jacak, Jaroslaw; Preiner, Johannes; Gimona, Mario
• Is Part Of: Journal of extracellular vesicles. Volume 10:Issue 12(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-10-20
• Subjects: atomic force microscopy (AFM) -- extracellular vesicles (EVs) -- label‐free sensors -- quartz crystal microbalance (QCM); Cells -- Mechanical properties -- Periodicals; Transport Vesicles; Cells -- Mechanical properties; Periodicals; Fulltext; Internet Resources; Periodicals; Electronic journals; Periodicals; 571.63
• DOI: 10.1002/jev2.12156
• Languages: English
• ISSNs: 2001-3078

Abstract

Abstract: Interest in mesenchymal stem cell derived extracellular vesicles (MSC‐EVs) as therapeutic agents has dramatically increased over the last decade. Current approaches to the characterization and quality control of EV‐based therapeutics include particle tracking techniques, Western blotting, and advanced cytometry, but standardized methods are lacking. In this study, we established and verified quartz crystal microbalance (QCM) as highly sensitive label‐free immunosensing technique for characterizing clinically approved umbilical cord MSC‐EVs enriched by tangential flow filtration and ultracentrifugation. Using QCM in conjunction with common characterization methods, we were able to specifically detect EVs via EV (CD9, CD63, CD81) and MSC (CD44, CD49e, CD73) markers. Furthermore, analysis of QCM dissipation versus frequency allowed us to quantitatively determine the ratio of marker‐specific EVs versus non‐vesicular particles (NVPs) – a parameter that cannot be obtained by any other technique so far. Additionally, we characterized the topography and elasticity of these EVs by atomic force microscopy (AFM), enabling us to distinguish between EVs and NVPs in our EV preparations. This measurement modality makes it possible to identify EV sub‐fractions, discriminate between EVs and NVPs, and to characterize EV surface proteins, all with minimal sample preparation and using label‐free measurement devices with low barriers of entry for labs looking to widen their spectrum of characterization techniques. Our combination of QCM with impedance measurement (QCM‐I) and AFM measurements provides a robust multi‐marker approach to the characterization of clinically approved EV therapeutics and opens the door to improved quality control.